The proposed guidance indicates certain Class I and Class II medical devices that “are sufficiently well-understood and do not present risks that require premarket notification (510(k)) review to assure their safety and effectiveness,” according to the document.
The draft guidance identifies certain classified devices from a range of specialties, including anesthesiology, cardiology, dental, gastroenterology and urology. The identified devices are deemed low risk, therefore not requiring all the premarket submission requirements, according to the report.
More articles on the FDA:
On heels of Google’s announcement, FDA to regulate genetic health tests
FDA drug, device import refusals rise due to improper registration
Only about 0.1% of mHealth apps are FDA-approved
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.